Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Cash from Financing Activities (2016 - 2025)

Conmed's Cash from Financing Activities history spans 16 years, with the latest figure at -$37.4 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 26.83% year-over-year to -$37.4 million; the TTM value through Dec 2025 reached -$135.8 million, up 10.05%, while the annual FY2025 figure was -$135.8 million, 10.05% up from the prior year.
  • Cash from Financing Activities reached -$37.4 million in Q4 2025 per CNMD's latest filing, up from -$43.5 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $159.1 million in Q2 2022 to a low of -$58.8 million in Q4 2023.
  • Average Cash from Financing Activities over 5 years is -$13.7 million, with a median of -$27.5 million recorded in 2025.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 820.17% in 2022, then crashed 610.34% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$40.8 million in 2021, then surged by 128.23% to $11.5 million in 2022, then plummeted by 610.34% to -$58.8 million in 2023, then increased by 13.1% to -$51.1 million in 2024, then increased by 26.83% to -$37.4 million in 2025.
  • Per Business Quant, the three most recent readings for CNMD's Cash from Financing Activities are -$37.4 million (Q4 2025), -$43.5 million (Q3 2025), and -$26.5 million (Q2 2025).